Cargando…

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis

BACKGROUND: For patients with MS, medication switches increase the risk of disease reactivation. OBJECTIVE: Compare discontinuation rates due to treatment failure or side effects between teriflunomide and dimethyl fumarate, and investigate clinical variables affecting discontinuation rates. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norborg, Hilde, Riise, Trond, Myhr, Kjell-Morten, Grytten, Nina, Wergeland, Stig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209840/ https://www.ncbi.nlm.nih.gov/pubmed/34188949 http://dx.doi.org/10.1177/20552173211022027

Ejemplares similares

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry
por: Benjaminsen, Espen, et al.
Publicado: (2019)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
por: Allan, Michelle, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Tolerability and discontinuation rates in teriflunomide-treated patients: A real-world clinical experience
por: Alnajashi, Hind A., et al.
Publicado: (2018)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
por: Lunde, Hanne Marie Bøe, et al.
Publicado: (2017)

Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study
por: Bjørnevik, Kjetil, et al.
Publicado: (2016)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
por: De Masi, Roberto, et al.
Publicado: (2021)

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2019)

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
por: Alroughani, Raed, et al.
Publicado: (2017)

Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva(®)) in Patients with Multiple Sclerosis: An Observational Retrospective Study
por: Abolfazli, Roya, et al.
Publicado: (2023)

Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study
por: Eid, Karine, et al.
Publicado: (2021)

Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study
por: Willumsen, Johannes Sverre, et al.
Publicado: (2022)

Employment among Patients with Multiple Sclerosis-A Population Study
por: Bøe Lunde, Hanne Marie, et al.
Publicado: (2014)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
por: Hallin, Erik I., et al.
Publicado: (2022)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
por: Zhang, Yao, et al.
Publicado: (2022)

Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study
por: Bjørnevik, Kjetil, et al.
Publicado: (2016)

Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study
por: Cortese, Marianna, et al.
Publicado: (2015)

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry
por: Jiang, Xiaotong, et al.
Publicado: (2023)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Chinea, Angel, et al.
Publicado: (2020)

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2023)

Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model
por: Wergeland, Stig, et al.
Publicado: (2011)

Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis
por: Oveland, Eystein, et al.
Publicado: (2021)

Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
por: Hendin Travis, Lori, et al.
Publicado: (2018)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model
por: Fjær, Sveinung, et al.
Publicado: (2013)

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
por: Min, Jinny, et al.
Publicado: (2019)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4hhee8r4d8tes3m5so6dvncguk